Literature DB >> 31866405

Mechanism of danshensu-induced inhibition of abnormal epidermal proliferation in psoriasis.

Jinjing Jia1, Xiumei Mo1, Junfeng Liu1, Fenggen Yan1, Ning Wang2, Ying Lin1, Hongyi Li1, Yan Zheng3, Dancan Chen4.   

Abstract

Psoriasis is a chronic, inflammatory skin disease with high incidence and high rates of relapse, for which no satisfactory treatments are currently available. Yes-associated protein (YAP) is highly expressed in psoriasis and may regulate the proliferation and apoptosis of keratinocytes. Danshen is a traditional Chinese medicine, commonly used in the treatment of psoriasis. Danshensu is the most abundant water-soluble component of Danshen, but its therapeutic mechanism is still unclear. In this study, MTT was used to detect the effects of different danshensu concentrations (0.125, 0.25, 0.5 mmol/l) on the proliferation of an M5-based psoriasis cell model. The effects of danshensu on cell cycle and apoptosis were detected by flow cytometry. Cyclins and apoptosis-related proteins were evaluated by Western blot. Danshensu (20, 40, 80 mg/kg/day) was administered intraperitoneally to the imiquimod (IMQ) psoriasis mouse model. After 7 days, the expression of YAP in the lesions was detected by immunohistochemistry and Western blot. We found that danshensu reduced the expression of YAP in the M5 psoriasis cell model, inhibited cell proliferation, induced cell cycle arrest in G0/G1 phase, and promoted cell apoptosis. All these effects were partly reverted by YAP overexpression. The skin lesions of IMQ mice were thinned and the scales reduced after intragastric administration of danshensu, which also resulted in dose-dependent inhibition of YAP expression. We concluded that danshensu prevents abnormal epidermis proliferation in psoriasis possibly by modulating YAP expression. Our work can provide a theoretical basis for the clinical application of Danshen in the treatment of psoriasis.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Danshen; Danshensu; Keratinocytes; Psoriasis; Yes-associated protein

Mesh:

Substances:

Year:  2019        PMID: 31866405     DOI: 10.1016/j.ejphar.2019.172881

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  A Traditional Chinese Medicine Formula Danshen Baibixiao Ameliorates Imiquimod-Induced Psoriasis-Like Inflammation in Mice.

Authors:  Xiaoqi Jin; Hongfeng Xu; Chuanqi Huang; Haoran Ma; Xin Xiong; Lu Cheng; Fuqian Wang; Yan Feng; Geng Zhang
Journal:  Front Pharmacol       Date:  2021-12-03       Impact factor: 5.810

Review 2.  Promising Strategies in Plant-Derived Treatments of Psoriasis-Update of In Vitro, In Vivo, and Clinical Trials Studies.

Authors:  Martyna Nowak-Perlak; Krzysztof Szpadel; Izabella Jabłońska; Monika Pizon; Marta Woźniak
Journal:  Molecules       Date:  2022-01-18       Impact factor: 4.411

3.  Mechanism of Huoluo Xiaoling Dan in the Treatment of Psoriasis Based on Network Pharmacology and Molecular Docking.

Authors:  Ke Gong; Wen Guo; Kaiqing Du; Fang Wang; Mengli Li; Jianhui Guo
Journal:  Evid Based Complement Alternat Med       Date:  2022-02-27       Impact factor: 2.629

Review 4.  Role of Yes-Associated Protein in Psoriasis and Skin Tumor Pathogenesis.

Authors:  Jinjing Jia; Yuqian Wang; Xiumei Mo; Dacan Chen
Journal:  J Pers Med       Date:  2022-06-16

5.  Xiao-Yin-Fang Therapy Alleviates Psoriasis-like Skin Inflammation Through Suppressing γδT17 Cell Polarization.

Authors:  Xilin Zhang; Xiaorui Li; Youdong Chen; Bingjie Li; Chunyuan Guo; Peng Xu; Zengyang Yu; Yangfeng Ding; Yuling Shi; Jun Gu
Journal:  Front Pharmacol       Date:  2021-04-16       Impact factor: 5.810

6.  Danshensu alleviates bleomycin-induced pulmonary fibrosis by inhibiting lung fibroblast-to-myofibroblast transition via the MEK/ERK signaling pathway.

Authors:  Huaman Liu; Xinyue Zhang; Yumeng Shao; Xuehong Lin; Feng Dong; Xue Liu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.